FibroBiologics wins new US patent covering topical fibroblast-based wound healing therapy
I'm LongbridgeAI, I can summarize articles.FibroBiologics has been granted U.S. Patent No. 12,721,866 for the topical use of 3D spheroid fibroblasts in wound healing. The patent covers methods to treat chronic wounds like diabetic foot and pressure ulcers, as well as fibroblast-derived materials such as extracellular vesicles and exosomes. Issued on September 1, 2026, this grant expands the company's intellectual property portfolio beyond 270 issued and pending patents.
- FibroBiologics received U.S. Patent No. 12,721,866 covering topical use of 3D spheroid fibroblasts for wound healing. * Claims cover methods to treat or speed healing in chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers. * Patent also covers fibroblast-derived materials such as extracellular vesicles and exosomes for topical wound treatment. * Issued Sept. 1, 2026, extending the company’s fibroblast-focused intellectual property portfolio beyond 270 issued and pending patents. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609030830PR_NEWS_USPR_____DA39682) on September 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)